BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 1719542)

  • 1. Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors.
    Shih CK; Rose JM; Hansen GL; Wu JC; Bacolla A; Griffin JA
    Proc Natl Acad Sci U S A; 1991 Nov; 88(21):9878-82. PubMed ID: 1719542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors.
    Sardana VV; Emini EA; Gotlib L; Graham DJ; Lineberger DW; Long WJ; Schlabach AJ; Wolfgang JA; Condra JH
    J Biol Chem; 1992 Sep; 267(25):17526-30. PubMed ID: 1381350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.
    Richman D; Shih CK; Lowy I; Rose J; Prodanovich P; Goff S; Griffin J
    Proc Natl Acad Sci U S A; 1991 Dec; 88(24):11241-5. PubMed ID: 1722324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The catalytic functions of chimeric reverse transcriptases of human immunodeficiency viruses type 1 and type 2.
    Shaharabany M; Hizi A
    J Biol Chem; 1992 Feb; 267(6):3674-8. PubMed ID: 1371274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of chimeric human immunodeficiency virus types 1 and 2 reverse transcriptases for structure-function analysis and for mapping susceptibility to nonnucleoside inhibitors.
    Yang G; Song Q; Charles M; Drosopoulos WC; Arnold E; Prasad VR
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(4):326-33. PubMed ID: 8601218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors.
    Condra JH; Emini EA; Gotlib L; Graham DJ; Schlabach AJ; Wolfgang JA; Colonno RJ; Sardana VV
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1441-6. PubMed ID: 1380789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-->isoleucine and tyrosine 188-->leucine), resistant to nonnucleoside inhibitors.
    Loya S; Bakhanashvili M; Tal R; Hughes SH; Boyer PL; Hizi A
    AIDS Res Hum Retroviruses; 1994 Aug; 10(8):939-46. PubMed ID: 7529032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of the chimeric reverse transcriptase of simian immunodeficiency virus sensitive to nonnucleoside reverse transcriptase inhibitor.
    Isaka Y; Sato A; Kawauchi S; Suyama A; Miki S; Hayami M; Fujiwara T
    Microbiol Immunol; 1998; 42(3):195-202. PubMed ID: 9570285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150).
    Mellors JW; Im GJ; Tramontano E; Winkler SR; Medina DJ; Dutschman GE; Bazmi HZ; Piras G; Gonzalez CJ; Cheng YC
    Mol Pharmacol; 1993 Jan; 43(1):11-6. PubMed ID: 7678690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5 "- (4"-amino-1",2"-oxathiole-2",2"-dioxide)thymine (TSAO-T).
    Balzarini J; Pérez-Pérez MJ; San-Félix A; Camarasa MJ; Bathurst IC; Barr PJ; De Clercq E
    J Biol Chem; 1992 Jun; 267(17):11831-8. PubMed ID: 1376314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous mutations at Tyr-181 and Tyr-188 in HIV-1 reverse transcriptase prevents inhibition of RNA-dependent DNA polymerase activity by the bisheteroarylpiperazine (BHAP) U-90152s.
    Fan N; Rank KB; Evans DB; Thomas RC; Tarpley WG; Sharma SK
    FEBS Lett; 1995 Aug; 370(1-2):59-62. PubMed ID: 7544302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.
    Spence RA; Kati WM; Anderson KS; Johnson KA
    Science; 1995 Feb; 267(5200):988-93. PubMed ID: 7532321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity.
    Kroeger Smith MB; Rouzer CA; Taneyhill LA; Smith NA; Hughes SH; Boyer PL; Janssen PA; Moereels H; Koymans L; Arnold E
    Protein Sci; 1995 Oct; 4(10):2203-22. PubMed ID: 8535257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.
    Dueweke TJ; Pushkarskaya T; Poppe SM; Swaney SM; Zhao JQ; Chen IS; Stevenson M; Tarpley WG
    Proc Natl Acad Sci U S A; 1993 May; 90(10):4713-7. PubMed ID: 7685109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors.
    Larder BA
    Antimicrob Agents Chemother; 1992 Dec; 36(12):2664-9. PubMed ID: 1282792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis.
    de Vreese K; Debyser Z; Vandamme AM; Pauwels R; Desmyter J; de Clercq E; Anné J
    Virology; 1992 Jun; 188(2):900-4. PubMed ID: 1374986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amino acid substitutions in HIV-1 reverse transcriptase with corresponding residues from HIV-2. Effect on kinetic constants and inhibition by non-nucleoside analogs.
    Bacolla A; Shih CK; Rose JM; Piras G; Warren TC; Grygon CA; Ingraham RH; Cousins RC; Greenwood DJ; Richman D
    J Biol Chem; 1993 Aug; 268(22):16571-7. PubMed ID: 7688367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allosteric inhibition of human immunodeficiency virus type 1 reverse transcriptase by tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione compounds.
    Debyser Z; Pauwels R; Andries K; Desmyter J; Engelborghs Y; Janssen PA; De Clercq E
    Mol Pharmacol; 1992 Jan; 41(1):203-8. PubMed ID: 1370707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase.
    Mellors JW; Dutschman GE; Im GJ; Tramontano E; Winkler SR; Cheng YC
    Mol Pharmacol; 1992 Mar; 41(3):446-51. PubMed ID: 1372083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutants.
    Balzarini J; Karlsson A; Sardana VV; Emini EA; Camarasa MJ; De Clercq E
    Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6599-603. PubMed ID: 7517553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.